Talis Biomedical Corporation reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 192.04 million compared to USD 91.13 million a year ago. Basic loss per share from continuing operations was USD 8.48 compared to USD 42.98 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.98 USD | -1.97% | -3.44% | +20.54% |
08/05 | Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02/04 | North American Morning Briefing : Stocks Seen -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+20.54% | 16.36M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- TLIS Stock
- News Talis Biomedical Corporation
- Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021